The vendor evaluation playbook most life sciences commercial teams use was built for general enterprise software. It doesn't account for pharmacovigilance obligations, MLR review workflows, or the compliance exposure that comes with artificial intelligence touching HCP interactions in a regulated promotional environment. Those gaps don't appear in demos. They surface six months into deployment when an adverse event signal runs through a system that wasn't designed to recognize it, or when AI-generated content exits without an audit trail.
You need different criteria. Here's what to require.
The operating environment is the variable most evaluations ignore. Life sciences organizations run on data types: electronic health records, clinical trial data, pharmacovigilance signals, genomics outputs, biomarkers. Each carries distinct regulatory obligations and governance requirements. A vendor experienced in retail or financial services AI hasn't encountered these data environments at a systems level. They've encountered them as a sales pitch.
The pharmaceutical industry adds a layer of complexity that doesn't exist in adjacent sectors. Field medical and commercial teams work inside MLR review processes. Content that reaches healthcare providers requires an audit trail. Generative AI that produces promotional material without those controls creates compliance exposure that won't be visible until it becomes a regulatory problem. The life sciences industry has watched vendors make this mistake repeatedly — systems deployed with capability that functions, in environments that can't accommodate that function safely.
The standard enterprise evaluation (demo, pilot, reference check, decision) doesn't surface these problems. You need a different set of questions and a different standard of proof.
Life sciences data depth. The first filter is whether the vendor has production experience with the data types your commercial operations actually run on. Clinical trial data has provenance requirements and governance structure that differ from standard enterprise data. Pharmacovigilance data carries reporting obligations; an AI system processing it needs to recognize what it's handling and what obligations attach to it. Biomarkers and genomics data require a vendor team that understands why those data types exist in a commercial context, not just that they do.
Ask for documented production deployments, not pilots, involving clinical trial data and pharmacovigilance workflows. A vendor who can't provide these doesn't have the experience the life sciences industry requires.
Regulatory compliance as architecture, not configuration. Pharmacovigilance processing, 21 CFR Part 11 environments, and MLR review workflows are design constraints. A vendor who treats regulatory compliance as a layer added on top of a general platform is telling you something important: the platform wasn't built for your environment. Ask how their system handles a potential pharmacovigilance signal embedded in unstructured data. Ask what their validation documentation looks like for GxP environments. A qualified vendor answers those questions without having to check with engineering.
Specificity about which AI technologies do what. Machine learning, natural language processing, deep learning, generative AI, predictive analytics, and computer vision are not interchangeable. Each addresses a different problem. A vendor who describes their platform as AI-powered without mapping specific AI technologies to specific use cases is either being vague intentionally or doesn't understand their own capability boundaries.
For commercial operations specifically: natural language processing for call transcript analysis, predictive analytics for market access and demand modeling, and generative AI for MLR-ready content generation are distinct technical domains. Know which capabilities are proprietary and which are wrapper implementations on third-party models. Intelligent automation that sits on top of a single third-party model is fragile. A platform with real technical depth in the life sciences industry will show you where its architecture actually lives.
Human-in-the-loop as an architectural requirement. No production AI deployment in pharma commercial should operate without meaningful human review at defined points. This isn't a limitation — it's the correct design for environments where an error has compliance or HCP relationship consequences. The question isn't whether the vendor supports human oversight. It's whether their system is built around it or treats it as friction.
Ask how their platform handles escalations, confidence thresholds, and edge cases. Intelligent automation that can't surface its own uncertainty to a human reviewer is automation that will eventually produce a problem you didn't anticipate.
Commercial-specific track record, not just life sciences credentials broadly. The life sciences industry spans drug discovery and development, clinical development, diagnostics, genomics research, biotech lab automation, and robotics. Pharma commercial operations is a distinct domain from all of them. A vendor with deep experience in clinical development doesn't automatically understand field force enablement, KAM analytics, or promotional content workflows. AI in life sciences and healthcare is a large category. Press them to be specific.
Require references from pharma commercial teams specifically. Ask about experience with patient engagement programs, launch execution, and market access analytics, not general life sciences organizations with AI deployments in non-commercial functions. Data science capabilities built for clinical development don't transfer directly to commercial operations without teams who have navigated that transition deliberately.
Four questions produce the clearest signal in an evaluation.
First: describe a production deployment in pharma commercial where something went wrong and how you fixed it. Vendors with real deployments answer this specifically. Vendors running on demo capability deflect to case study language.
Second: how does your team handle pharmacovigilance data operationally, not in the abstract but procedurally? What is your protocol when a potential adverse event signal appears in data your system is processing? The answer tells you whether they understand the regulatory obligation attached to that signal or whether they're treating it as data.
Third: how does your implementation approach account for the gap between clinical development timelines and commercial launch windows? The clinical-to-commercial transition is where most AI deployments stall in the pharmaceutical industry. A vendor who can speak to this specifically has navigated it before.
Fourth: what does your validation process look like for a 21 CFR Part 11 environment, and can you share documentation? The answer tells you whether they've been through GxP validation or whether you're funding their first attempt at it.
A vendor built for pharma commercial operations will answer the pharmacovigilance and clinical trial data questions without hesitation. They'll have validation documentation ready. They'll reference pharma commercial teams specifically, not aggregate "life sciences and healthcare" client lists, and facilitate reference conversations without resistance.
They'll also tell you what they don't do. A platform that claims comprehensive capability across drug discovery and development, clinical trials, diagnostics, genomics, patient engagement, robotics, and commercial operations is strong in some of those areas and weaker in others. Make them be specific about where their production deployments actually live. A vendor who draws that line clearly is more trustworthy, not less capable.
The evaluation process itself signals fit. A vendor who responds to detailed questions about your regulatory environment with specific answers and follows up with documentation is built for this environment. One who redirects to demos whenever you push on compliance is not.
Invisible partners with pharma and life sciences organizations to deploy AI operations designed for regulated commercial environments: MLR review workflows, field force enablement, and market access analytics. See how we work with the life sciences industry at invisibletech.ai/industries/life-sciences, or get started.
Pharma commercial operations combine regulatory compliance obligations, pharmacovigilance data handling requirements, and MLR review processes that don't exist in general enterprise environments. A vendor qualified for retail or financial services AI isn't automatically qualified for a regulated life sciences deployment. Evaluation criteria need to reflect those constraints from the first conversation, not as an afterthought after you've already committed to a pilot.
Ask them to walk through what happens when a potential adverse event signal surfaces in data their system is processing. A qualified vendor has a documented protocol and can explain how it connects to your reporting obligations. A vendor who hasn't worked through this gives you a generic answer about compliance support. The operational specificity of the response is the signal.
Every production AI deployment in pharma commercial should have defined human review points for outputs with compliance exposure: content going to healthcare providers, analytics informing market access decisions, and processes touching pharmacovigilance data. Human-in-the-loop should be an architectural feature, not an add-on. Require vendors to show you how it functions in their platform, not describe it in the abstract.
Ask for documented production deployments involving clinical trial data, not pilots. Push on governance specifics: how was data access structured, what were the audit trail requirements, and how did the team handle the transition from clinical development to commercial use? Vendors with real experience answer with operational detail. Vendors with surface-level experience don't have those details ready.
Most platforms that claim full spectrum coverage are strong in one domain and weaker in others. A system built around drug discovery and clinical development typically lacks depth in commercial field enablement and MLR content workflows. Evaluate the specific use cases you're deploying for rather than the total capability claim. A vendor who's transparent about where their platform performs best is more credible than one who claims everything.
Client lists tell you who paid them, not what they built. Ask for specifics: which AI technologies were deployed, what the data environment looked like, what regulatory requirements were in scope, and what the implementation timeline was. A vendor with genuine life sciences industry experience answers with operational detail. One relying on name recognition doesn't have those specifics ready.
Ask directly whether they've completed a validation protocol for a 21 CFR Part 11 environment and request the documentation. Vendors who've been through validation have IQ/OQ/PQ documentation and a team that understands what's in it. Vendors who haven't will claim they're "validation-ready" without documentation to back it. That distinction tells you what your implementation will look like before you've committed to it.
